AAVAnc80-hOTOF

DRUG2 trials

Sponsors

Akouos Inc.

Conditions

Otoferlin gene-mediated hearing loss

Phase 1

A Phase 1/2 Trial of AAVAnc80-hOTOF Gene Therapy in Individuals with Sensorineural Hearing Loss due to Biallelic Otoferlin Gene (OTOF) Mutations

Not yet recruitingCTIS2023-505128-76-00

Akouos Inc.Otoferlin gene-mediated hearing loss

Target: 2Updated: 2023-10-05

Phase 2

An Evaluation of the Long Term Safety and Efficacy of AAVAnc80-hOTOF Gene Therapy in Individuals with Sensorineural Hearing Loss due to Otoferlin Gene (OTOF) Mutations

RecruitingCTIS2024-512584-31-00

Akouos Inc.Otoferlin gene-mediated hearing loss

Start: 2024-11-11Target: 2Updated: 2025-08-05